Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.

10 novembre 2026 mis à jour par: Sanofi

A Nested Phase 3, Randomized, Active-controlled, Open-label, 2-arm, Multicenter Study to Investigate the Immunogenicity and Safety of Sanofi's Hexavalent DTaP-IPV-HB-PRP~T Combined Vaccine Given at 2, 4, and 6 Months of Age Compared With DTaP-IPV//PRP~T Combined Vaccine (Pentaxim™) Given at 2, 4, and 6 Months of Age Administered With a Monovalent Hepatitis B Vaccine Given at 1 and 6 Months of Age to Healthy Chinese Infants Who Previously Received a Birth Dose of Monovalent Hepatitis B Vaccine

The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.

Study details include:

  • The study duration per participant will be approximately 18 months.
  • The study vaccines administration:
  • Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA.
  • Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

720

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Trial Transparency email recommended (Toll free for US & Canada)
  • Numéro de téléphone: option 6 800-633-1610
  • E-mail: Contact-US@sanofi.com

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

1 mois à 1 mois (Enfant)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine
  • Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, and in both cases medically stable as assessed by the investigator
  • Participants who are born to mothers with documented HBsAg seronegative status
  • Informed consent form has been signed and dated by the parent(s) or other LAR
  • Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures

Exclusion Criteria:

  • Known/suspected immunodeficiency; immunosuppressive therapy since birth; long-term systemic corticosteroid therapy
  • History of diagnosis of Hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection
  • History of seizure or significant stable or progressive neurological disorders
  • Known systemic hypersensitivity to any study intervention components, or history of a life-threatening reaction to study interventions or product with the same substances
  • Known thrombocytopenia
  • Bleeding disorder
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Any vaccine given since birth or planned receipt of any vaccine until 1 month after the completion of the primary series vaccination with the study interventions except for Bacille Calmette-Guérin (BCG) vaccine and meningococcal polysaccharide vaccine-A.
  • Previous vaccination against D, T, pertussis, poliomyelitis, Hep B (except the dose of Hep B given at birth) or Haemophilus influenzae type b infections (since birth) with an investigational or marketed vaccine.
  • Receipt of immune globulins, blood or blood-derived products
  • Participation in another clinical study for a vaccine, drug, medical device, or medical procedure at the time of study enrollment or planned participation during the present study period.
  • Known personal or maternal history of HIV or HCV seropositivity
  • Being in an emergency setting
  • Identified as a natural or adopted child of the Investigator/study site employee with direct involvement in the study

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Group 1 (the investigational group)

Hexaxim at 2, 4 and 6 MoA

Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection

Comparateur actif: Group 2 (the comparator group)

Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA

Pharmaceutical form:Freeze-dried PRP~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection

Pharmaceutical form: Depending on the brand procured Route of administration:IM injection

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Délai: Day181

Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA

Day181

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Baseline, pre-vaccination sample
Délai: Day 31

Ab concentrations/titers for each Ag

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 μg/mL
  • Anti-Hep B Ab concentrations ≥10 mIU/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
Day 31
1 month after the last dose of primary series:
Délai: Day181

Ab concentrations/titers for each Ag

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 μg/mL and ≥1.0 μg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
  • Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL Ab individual concentration/titer ratios for all antigens except for Hep B) (post-Dose 3/pre-Dose 1) Anti-Hep B Ab individual concentration ratio (post-Dose 4 Hep B/pre-Dose 2 Hep B in the investigational group, or post-Dose 3 Hep B/post-Dose 2 Hep B in the comparator group) Note: Dose 1 Hep B corresponds to the dose of Hep B vaccine given at birth.
Day181
Before the booster dose:
Délai: Day 511

Ab concentrations/titers for each

Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
  • Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL
Day 511
1 month after the booster dose:
Délai: Day 541

Ab concentrations/titers for each Ag of Pentaxim

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Seroconversion for anti-PT and anti-FHA defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Booster to post-Booster Ab individual concentration/titer ratios for all antigens (post-Booster/pre-Booster)
Day 541
Presence of immediate unsolicited adverse events (AEs)
Délai: 30 minutes after each and any vaccination
30 minutes after each and any vaccination
Presence of solicited injection site reactions
Délai: for 8 days, including the day of each and any vaccination

(pre-listed in the participant diary and case report form [CRF])

for 8 days, including the day of each and any vaccination
Presence of solicited systemic reactions
Délai: for 8 days, including the day of each and any vaccination

(pre-listed in the participant diary and CRF)

for 8 days, including the day of each and any vaccination
Presence of unsolicited AEs
Délai: for 30 days, including the day of each and any vaccination
for 30 days, including the day of each and any vaccination
Presence of serious adverse events (SAEs)
Délai: up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
Presence of related SAEs and fatal case regardless of causality
Délai: Day 541
Day 541
Presence of AEs leading to study discontinuation
Délai: Day 541
Day 541

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

28 décembre 2026

Achèvement primaire (Estimé)

27 avril 2028

Achèvement de l'étude (Estimé)

30 juillet 2029

Dates d'inscription aux études

Première soumission

10 novembre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • A3L00054
  • U1111-1227-3420 (Identificateur de registre: ICTRP)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner